Fraunhofer Institute for Translational Medicine and Pharmacology ITMP
Fraunhofer Institute for Translational Medicine and Pharmacology ITMP

Publications

Selected publications

2023

  • Bonnekoh H., Krause K., & Kolkhir P. (2023). "Chronic recurrent wheals–If not chronic spontaneous urticaria, what else?" Allergologie Select, 7, 8.
  • Bonnekoh H., Krause K., & Kolkhir P. (2023). "Chronisch rezidivierend auftretende Quaddeln–Woran sollte neben einer chronischen spontanen Urtikaria gedacht werden?" Allergologie, 46(1), 41.
  • Charalampous P., Haagsma J. A., Jakobsen L. S., Gorasso V., Noguer I., Padron-Monedero A., Sarmiento R., Santos J. V., McDonald S. A., & Plass D. (2023). "Burden of infectious disease studies in Europe and the United Kingdom: a review of methodological design choices." Epidemiology & Infection, 1-32.
  • Craig T. J., Reshef A., Li H. H., Jacobs J. S., Bernstein J. A., Farkas H., Yang W. H., Stroes E. S. G., Ohsawa I., Tachdjian R., Manning M. E., Lumry W. R., Saguer I. M., Aygören-Pürsün E., Ritchie B., Sussman G. L., Anderson J., Kawahata K., Suzuki Y., Staubach P., Treudler R., Feuersenger H., Glassman F., Jacobs I., & Magerl M. (2023). "Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial." The Lancet, 401(10382), 1079-1090. doi:https://doi.org/10.1016/S0140-6736(23)00350-1
  • Förster-Ruhrmann U., Stergioudi D., Szczepek A. J., Fluhr J. W., Zuberbier T., Olze H., & Bergmann K.-C. (2023). "A real-life comparison of pulmonary and nasal outcomes in patients with severe asthma and nasal polyposis treated with T2-biologics." World Allergy Organization Journal, 16(2), 100746. doi:https://doi.org/10.1016/j.waojou.2023.100746
  • Franke K., Bal G., Li Z., Zuberbier T., & Babina M. (2023). "CREB Is Activated by the SCF/KIT Axis in a Partially ERK-Dependent Manner and Orchestrates Survival and the Induction of Immediate Early Genes in Human Skin Mast Cells." International Journal of Molecular Sciences, 24(4), 4135. Retrieved from https://www.mdpi.com/1422-0067/24/4/4135
  • Frischbutter S., Durek P., Witkowski M., Angermair S., Treskatsch S., Maurer M., Radbruch A., & Mashreghi M.-F. (2023). "Serum TGF-β as a predictive biomarker for severe disease and fatality of COVID-19." European Journal of Immunology, 53(10), 2350433. doi:https://doi.org/10.1002/eji.202350433
  • Klimek L., Brehler R., Bergmann K.-C., Casper I., Klimek F., Hagemann J., Polk M.-L., & Cuevas M. (2023). "Avoidance measures for mite allergy—an update." Allergo Journal International, 32(1), 18-27.
  • Klimek L., Brehler R., Casper I., Klimek F., Hagemann J., Cuevas M., & Bergmann K.-C. (2023). "Allergen immunotherapy in house dust mite-associated allergic rhinitis: efficacy of the 300 IR mite tablet." Allergo Journal International, 32(1), 10-17.
  • Krišto M., Lugović-Mihić L., Muñoz M., Rupnik M., Mahnic A., Ozretić P., Jaganjac M., Ćesić D., & Kuna M. (2023). "Gut Microbiome Composition in Patients with Chronic Urticaria: A Review of Current Evidence and Data." Life, 13(1), 152.
  • Özçeker D., Can P. K., Terzi Ö., Ornek S. A., Değirmentepe Ece N., Kızıltac K., Sarac E., & Kocatürk E. (2023). "Differences between adult and pediatric chronic spontaneous urticaria from a cohort of 751 patients: Clinical features, associated conditions and indicators of treatment response." Pediatric Allergy and Immunology, 34(2), e13925. doi:https://doi.org/10.1111/pai.13925
  • Sousa-Pinto B., Jácome C., Pereira A. M., Regateiro F. S., Almeida R., Czarlewski W., Kulus M., Shamji M. H., Boulet L.-P., & Bonini M. (2023). "Development and validation of an electronic daily control score for asthma (e-DASTHMA): a real-world direct patient data study." The Lancet Digital Health, 5(4), e227-e238.
  • Sousa-Pinto B., Schünemann H. J., Sá-Sousa A., Vieira R. J., Amaral R., Anto J. M., Klimek L., Czarlewski W., Mullol J., Pfaar O., Bedbrook A., Brussino L., Kvedariene V., Larenas-Linnemann D. E., Okamoto Y., Ventura M. T., Agache I., Ansotegui I. J., Bergmann K. C., Bosnic-Anticevich S., Canonica G. W., Cardona V., Carreiro-Martins P., Casale T., Cecchi L., Chivato T., Chu D. K., Cingi C., Costa E. M., Cruz A. A., Del Giacco S., Devillier P., Eklund P., Fokkens W. J., Gemicioglu B., Haahtela T., Ivancevich J. C., Ispayeva Z., Jutel M., Kuna P., Kaidashev I., Khaitov M., Kraxner H., Laune D., Lipworth B., Louis R., Makris M., Monti R., Morais-Almeida M., Mösges R., Niedoszytko M., Papadopoulos N. G., Patella V., Pham-Thi N., Regateiro F. S., Reitsma S., Rouadi P. W., Samolinski B., Sheikh A., Sova M., Todo-Bom A., Taborda-Barata L., Toppila-Salmi S., Sastre J., Tsiligianni I., Valiulis A., Vandenplas O., Wallace D., Waserman S., Yorgancioglu A., Zidarn M., Zuberbier T., Fonseca J. A., & Bousquet J. (2023). "Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK-air® longitudinal study." Allergy, 78(4), 968-983. doi:https://doi.org/10.1111/all.15574

2022

  • Bergmann K.-C. (2022a). "Biology of house dust mites and storage mites." Allergo Journal International, 31(8), 272-278.
  • Bergmann K.-C. (2022b). "Frequency of sensitizations and allergies to house dust mites." Allergo Journal International, 31(8), 279-283.
  • Bergmann K.-C., Skowasch D., Timmermann H., Lindner R., Virchow J. C., Schmidt O., Koschel D., Neurohr C., Heck S., & Milger K. (2022). "Prevalence of patients with uncontrolled asthma despite NVL/GINA step 4/5 treatment in Germany." Journal of Asthma and Allergy, 897-906.
  • Bölke G., Tong X., Zuberbier T., Bousquet J., & Bergmann K.-C. (2022). "Extension of mepolizumab injection intervals as potential of saving costs in well controlled patients with severe eosinophilic asthma." World Allergy Organization Journal, 15(10), 100703.
  • Bonnekoh H., Butze M., & Metz M. (2022). "Characterization of the effects on pruritus by novel treatments for atopic dermatitis." JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 20(2), 150-156.
  • Chebib S., Meng C., Ludwig C., Bergmann K.-C., Becker S., Dierend W., & Schwab W. (2022). "Identification of allergenomic signatures in allergic and well-tolerated apple genotypes using LC-MS/MS." Food Chemistry: Molecular Sciences, 4, 100111.
  • Chen Y., Ye Y., Krauß P.-L., Löwe P., Pfeiffenberger M., Damerau A., Ehlers L., Buttgereit T., Hoff P., & Buttgereit F. (2022). "Age-related increase of mitochondrial content in human memory CD4+ T cells contributes to ROS-mediated increased expression of proinflammatory cytokines." Frontiers in Immunology, 13, 911050.
  • Craig T., Magerl M., Levy D. S., Reshef A., Lumry W. R., Martinez-Saguer I., Jacobs J. S., Yang W. H., Ritchie B., & Aygören-Pürsün E. (2022). "Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial." The Lancet, 399(10328), 945-955.
  • Francuzik W., Pažur K., Dalke M., Dölle-Bierke S., Babina M., & Worm M. (2022). "Serological profiling reveals hsa-miR-451a as a possible biomarker of anaphylaxis." JCI insight, 7(7).
  • Franke K., Kirchner M., Mertins P., Zuberbier T., & Babina M. (2022). "The SCF/KIT axis in human mast cells: Capicua acts as potent KIT repressor and ERK predominates PI3K." Allergy, 77(11), 3337-3349.
  • Gazzi T., Brennecke B., Atz K., Korn C., Sykes D., Forn-Cuni G., Pfaff P., Sarott R. C., Westphal M. V., & Mostinski Y. (2022). "Detection of cannabinoid receptor type 2 in native cells and zebrafish with a highly potent, cell-permeable fluorescent probe." Chemical Science, 13(19), 5539-5545.
  • Graf M., von Stuckrad S. L., Uruha A., Klotsche J., Zorn-Pauly L., Unterwalder N., Buttgereit T., Krusche M., Meisel C., & Burmester G. R. (2022). "SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies." RMD open, 8(1), e001934.
  • Kocaturk E., Saini S. S., Rubeiz C. J., & Bernstein J. A. (2022). "Existing and investigational medications for refractory chronic spontaneous urticaria: safety, adverse effects, and monitoring." The Journal of Allergy and Clinical Immunology: In Practice.
  • Metz M., & Raap U. (2022). "Neuigkeiten aus der aktuellen Leitlinie zu chronischem Pruritus." Die Dermatologie, 73(8), 609-612.
  • Ornek S. A., Orcen C., Church M. K., & Kocaturk E. (2022). "An evaluation of remission rates with first and second line treatments and indicators of antihistamine refractoriness in chronic urticaria." International Immunopharmacology, 112, 109198.
  • Redhu D., Franke K., Aparicio-Soto M., Kumari V., Pazur K., Illerhaus A., Hartmann K., Worm M., & Babina M. (2022). "Mast cells instruct keratinocytes to produce thymic stromal lymphopoietin: Relevance of the tryptase/protease-activated receptor 2 axis." Journal of Allergy and Clinical Immunology, 149(6), 2053-2061. e2056.
  • Sousa-Pinto B., Anto A., Berger M., Dramburg S., Pfaar O., Klimek L., Jutel M., Czarlewski W., Bedbrook A., Valiulis A., Agache I., Amaral R., Ansotegui I. J., Bastl K., Berger U., Bergmann K. C., Bosnic-Anticevich S., Braido F., Brussino L., Cardona V., Casale T., Canonica G. W., Cecchi L., Charpin D., Chivato T., Chu D. K., Cingi C., Costa E. M., Cruz A. A., Devillier P., Durham S. R., Ebisawa M., Fiocchi A., Fokkens W. J., Gemicioglu B., Gotua M., Guzmán M. A., Haahtela T., Ivancevich J. C., Kuna P., Kaidashev I., Khaitov M., Kvedariene V., Larenas-Linnemann D. E., Lipworth B., Laune D., Matricardi P. M., Morais-Almeida M., Mullol J., Naclerio R., Neffen H., Nekam K., Niedoszytko M., Okamoto Y., Papadopoulos N. G., Park H. S., Passalacqua G., Patella V., Pelosi S., Nhan P. T., Popov T. A., Regateiro F. S., Reitsma S., Rodriguez-Gonzales M., Rosario N., Rouadi P. W., Samolinski B., Sá-Sousa A., Sastre J., Sheikh A., Ulrik C. S., Taborda-Barata L., Todo-Bom A., Tomazic P. V., Toppila-Salmi S., Tripodi S., Tsiligianni I., Valovirta E., Ventura M. T., Valero A. A., Vieira R. J., Wallace D., Waserman S., Williams S., Yorgancioglu A., Zhang L., Zidarn M., Zuberbier J., Olze H., Antó J. M., Zuberbier T., Fonseca J. A., & Bousquet J. (2022). "Real-world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities." Clinical and Translational Allergy, 12(11). doi:ARTN e12208
  • 10.1002/clt2.12208
  • Sousa‐Pinto B., Anto A., Berger M., Dramburg S., Pfaar O., Klimek L., Jutel M., Czarlewski W., Bedbrook A., & Valiulis A. (2022). "Real‐world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities." Clinical and translational allergy, 12(11), e12208.
  • Ständer S., Zeidler C., Augustin M., Darsow U., Kremer A. E., Legat F. J., Koschmieder S., Kupfer J., Mettang T., & Metz M. (2022). "S2k guideline: Diagnosis and treatment of chronic pruritus." JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 20(10), 1387-1402.
  • Trendelenburg V., Dölle-Bierke S., Unterleider N., Alexiou A., Kalb B., Meixner L., Heller S., Lau S., Lee Y.-A., & Fauchère F. (2022). "Tolerance induction through non-avoidance to prevent persistent food allergy (TINA) in children and adults with peanut or tree nut allergy: rationale, study design and methods of a randomized controlled trial and observational cohort study." Trials, 23(1), 236.
  • Tsabouri S., Arasi S., Beken B., Church M. K., Alvaro‐Lozano M., Caffarelli C., Flohr C., Janmohamed S. R., Konstantinou G. N., & Lau S. (2022). "A European survey of management approaches in chronic urticaria in children: EAACI pediatric urticaria taskforce." Pediatric Allergy and Immunology, 33(1), e13674.
  • Wang Z., Franke K., Bal G., Li Z., Zuberbier T., & Babina M. (2022). "MRGPRX2-mediated degranulation of human skin mast cells requires the operation of Gαi, Gαq, Ca++ channels, ERK1/2 and PI3K—interconnection between early and late signaling." Cells, 11(6), 953.
  • Wang Z., Li Z., Bal G., Franke K., Zuberbier T., & Babina M. (2022). "β-arrestin-1 and β-arrestin-2 Restrain MRGPRX2-Triggered Degranulation and ERK1/2 Activation in Human Skin Mast Cells." Frontiers in Allergy, 3. doi:10.3389/falgy.2022.930233
  • Wiebe E., Huscher D., Schaumburg D., Palmowski A., Hermann S., Buttgereit T., Biesen R., Burmester G.-R., Palmowski Y., & Boers M. (2022). "Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease." Annals of the Rheumatic Diseases, 81(9), 1313-1322.
  • Wiebe E., Huscher D., Schaumburg D., Palmowski A., Hermann S., Buttgereit T., Biesen R., Burmester G.-R., Palmowski Y., Boers M., Stone J. H., Dejaco C., & Buttgereit F. (2022). "Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease." Annals of the Rheumatic Diseases, 81(9), 1313-1322. doi:10.1136/annrheumdis-2022-222339

2021

  • Bonadonna P., Brockow K., Niedoszytko M., Elberink H. O., Akin C., Nedoszytko B., Butterfield J. H., Alvarez-Twose I., Sotlar K., & Schwaab J. (2021). "COVID-19 vaccination in mastocytosis: recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)." The Journal of Allergy and Clinical Immunology: In Practice, 9(6), 2139-2144.
  • Darlenski R., Kozyrskyj A. L., Fluhr J. W., & Caraballo L. (2021). "Association between barrier impairment and skin microbiota in atopic dermatitis from a global perspective: unmet needs and open questions." Journal of Allergy and Clinical Immunology, 148(6), 1387-1393.
  • Fluhr J. W., Gueguen A., Legoupil D., Brenaut E., Abasq C., Araújo H., & Misery L. (2021). "Teledermatology in times of COVID-19 confinement: comparing patients’ and physicians’ satisfaction by the standardized brest teledermatology questionnaire." Dermatology, 237(2), 191-196.
  • Hofmann M. A., Fluhr J. W., Ruwwe‐Glösenkamp C., Stevanovic K., Bergmann K. C., & Zuberbier T. (2021). "Role of IL‐17 in atopy—A systematic review." Clinical and Translational Allergy, 11(6), e12047.
  • Krause T., Bonnekoh H., Dilling A., Nast A., & Metz M. (2021). "A distinctive bullous skin reaction associated with enfortumab vedotin‐ejfv treatment for metastatic urothelial cancer: A case report." JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 19, 1781-1783.
  • Krauss P.-L., Pfeiffenberger M., Damerau A., Buttgereit T., Chen Y., Gaber T., & Buttgereit F. (2021). "Production of IL-6 and phagocytosis are the most resilient immune functions in metabolically compromised human monocytes." Frontiers in Immunology, 12, 730672.
  • Legeas C., Misery L., ROUDOT A.-C., FICHEUX A.-S., & BRENAUT E. (2021). "Proposal for cut-off scores for sensitive skin on sensitive scale-10 in a group of adult women." Acta Dermato-Venereologica, 101(1).
  • Misery L., Brenaut E., Pierre O., Le Garrec R., Gouin O., Lebonvallet N., Abasq‐Thomas C., Talagas M., Le Gall‐ianotto C., & Besner‐Morin C. (2021). "Chronic itch: emerging treatments following new research concepts." British Journal of Pharmacology, 178(24), 4775-4791.
  • Misery L., Fluhr J.-W., Beylot-Barry M., Jouan N., Hamann P., Consoli S.-G., Schollhammer M., Charleux D., Bewley A., & Rathod D. (2021). Psychological and professional impact of COVID-19 lockdown on French dermatologists: Data from a large survey. Paper presented at the Annales de Dermatologie et de Venereologie.
  • Misery L., Morisset S., Séité S., Brenaut E., Ficheux A. S., Fluhr J., Delvigne V., & Taieb C. (2021). "Relationship between sensitive skin and sleep disorders, fatigue, dust, sweating, food, tobacco consumption or female hormonal changes: Results from a worldwide survey of 10 743 individuals." Journal of the European Academy of Dermatology and Venereology, 35(6), 1371-1376.
  • Muñoz M., Hegazy A. N., Brunner T. M., Holecska V., Marek R. M., Fröhlich A., & Löhning M. (2021). "Th2 cells lacking T-bet suppress naive and memory T cell responses via IL-10." Proceedings of the National Academy of Sciences, 118(6), e2002787118.
  • Pereira M. P., Zeidler C., Wallengren J., Halvorsen J. A., Weisshaar E., Garcovich S., Misery L., Brenaut E., Savk E., & Potekaev N. (2021). "Chronic nodular prurigo: a European cross-sectional study of patient perspectives on therapeutic goals and satisfaction." Acta Dermato-Venereologica, 101(2).
  • Pierre O., Fouchard M., Le Goux N., Buscaglia P., Leschiera R., Lewis R. J., Mignen O., Fluhr J. W., Misery L., & Le Garrec R. (2021). "Pacific-ciguatoxin-2 and brevetoxin-1 induce the sensitization of sensory receptors mediating pain and pruritus in sensory neurons." Marine Drugs, 19(7), 387.
  • Prado Acosta M., Goyette-Desjardins G., Scheffel J., Dudeck A., Ruland J., & Lepenies B. (2021). "S-Layer from Lactobacillus brevis modulates antigen-presenting cell functions via the Mincle-Syk-Card9 Axis." Frontiers in immunology, 12, 602067.
  • Werner R. N., Zidane M. T. C., Metz M., & Weyandt G. (2021). "Pruritus ani—Diagnostics and treatment: Recommendations from the updated German guidelines." coloproctology, 43, 97-105.
  • Wolf K., Kühn H., Boehm F., Gebhardt L., Glaudo M., Agelopoulos K., Ständer S., Ectors P., Zahn D., & Riedel Y. K. (2021). "A group of cationic amphiphilic drugs activates MRGPRX2 and induces scratching behavior in mice." Journal of Allergy and Clinical Immunology, 148(2), 506-522. e508.
  • Yanai K., Yoshikawa T., & Church M. K. (2021). "Efficacy and Safety of Non-brain Penetrating H1-Antihistamines for the Treatment of Allergic Diseases." The Functional Roles of Histamine Receptors, 193-214.

2020

  • Ständer S., Pereira M. P., Berger T., Zeidler C., Augustin M., Bobko S., Brenaut E., Chen S. C., Chisolm S., & Dalgard F. J. (2020). "IFSI-guideline on chronic prurigo including prurigo nodularis." Itch, 5(4), e42.